206876-12-2
Chemical Structure
Gylongiposide I
- CAS No.: 206876-12-2
- Formula:C46H76O16
- Molecular Weight:885.09
InChIKey: GCXPWGOMZLYWLE-PGSPPWFOSA-N
SMILES: O=C[C@@]12[C@]3([H])[C@]([C@]4([C@]([C@@](CC4)([H])[C@@](CO)(O)CC/C=C(C)\C)([H])CC3)C)(CC[C@@]1([H])C(C)([C@H](CC2)O[C@H]5[C@@H]([C@H]([C@H](CO5)O)O[C@H]6[C@@H]([C@H]([C@@H](CO6)O)O)O)O[C@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)C)O)O)O)C)C
Biological Activity: Gylongiposide I is a selective inhibitor against the enterovirus EV71 with an EC50 of 1.53 μM. Gylongiposide I exerts antiviral activity by reducing viral protein VP1 expression and viral genomic RNA levels. Gylongiposide I can be used in the development of anti-EV71 drugs related to hand, foot and mouth disease[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Gylongiposide I | 98.78% | Gylongiposide I is a selective inhibitor against the enterovirus EV71 with an EC50 of 1.53 μM. Gylongiposide I exerts antiviral activity by reducing viral protein VP1 expression and viral genomic RNA levels. Gylongiposide I can be used in the development of anti-EV71 drugs related to hand, foot and mouth disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yin F, et al. Novel dammarane-type glycosides from Gynostemma pentaphyllum. Chem Pharm Bull (Tokyo). 2004 Dec;52(12):1440-4. [Content Brief]
- [2]. Zhao H, et al. Enzymatic Biotransformation of Gypenoside XLIX into Gylongiposide I and Their Antiviral Roles against Enterovirus 71 In Vitro. Molecules. 2022 Jun 25;27(13):4094. [Content Brief]
